The Company

TI Solutions AG develops high-quality and flexible stimulation devices and treatment-planning tools for temporal interference (TI) research. The company was founded in December 2019 in Zurich, Switzerland, by the creators of the TI concept in collaboration with Z43 to specifically foster TI research.

TI Devices

The neurostimulation devices under development will support both alternating current and TI stimulation, multiple stimulation channels, a wide carrier-frequency range, flexible modulation, magnetic resonance imaging and electroencephalogram recording compatibility, and more.

Device Description

Continuously updated information about our TI devices can be found here.

Treatment-Planning Tools

The treatment-planning tools will provide high-quality visualization and optimization of alternating current and TI stimulation configurations based on electromagnetic simulations involving detailed, high-resolution representations of head anatomies of both humans and animals. Thanks to a state-of-the-art cloud-based modeling platform, simulations of complex and realistic setups can be performed without specialized software or hardware. A particular focus is placed on flexibility with regard to optimization criteria (for scientific exploration), good user guidance, and powerful visualization. In 2021, personalized treatment modeling will be added that allows the modeling of any anatomy as well as any electrode shape and placement.


Our team will provide all engineering services required for the optimal application of the developed TI devices and treatment-planning tools, such as troubleshooting support, replacement of defective devices, and repairs. We are happy to contribute to drafting research proposals and to perform simulations for the treatment planning if required. We are also interested in discussing and, if feasible, incorporating additional features into our devices and software tools.

The Science

Temporal Interference (TI) stimulation is a noninvasive technique that uses scalp electrodes to apply interfering electrical high-frequency currents to reach structures deep inside the brain. While the applied frequencies of the electric fields themselves are too high to induce neural firing, the frequency of the envelop can drive neural activity. This new concept holds great promise for both research and clinics as it may open up new experimental opportunities and may be used for selective deep brain stimulation to treat certain disorders without the necessity of surgically implanting electrodes within certain brain areas, which is still common practice today. 

Grossman N, Bono D, Dedic N, et al. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields.  Cell. 2017;169(6):1029‐1041.e16. doi:10.1016/j.cell.2017.05.024


The latest publications on TI stimulation can be found here.


Important updates and developments on TI related research can be found here.

The People

Ed Boyden

Prof. Ed Boyden is Y. Eva Tan Professor in Neurotechnology at MIT in Boston, USA, Professor of Biological Engineering and Brain and Cognitive Sciences at MIT’s McGovern Institute for Brain Research, and an Investigator at the Howard Hughes Medical Institute. He leads the Synthetic Neurobiology Group, which develops new biotechnological tools for probing, analyzing, and engineering brain circuits. He and Nir Grossman are inventors of the TI stimulation technology patent.

Nir Grossmann

Prof. Nir Grossman is a Lecturer at Imperial College London, a founding fellow of the UK Dementia Research Institute, and is affiliated with Imperial’s Centre for Bioinspired Technology and Centre for Neurotechnology, MIT’s Media Lab, and the McGovern Institute for Brain Research. His research focuses on the development of new tools and principles for neuromodulatory interventions for neurodegenerative diseases and other brain disorders. He and Ed Boyden are the inventors of the TI stimulation technology patent.

Henrich Kisker

Henrich Kisker holds various positions as internal and external adviser on corporate, legal, and financial matters for a number of international companies. Since 2005, he has also been a member of the advisory board (“Bankrat”) of one of the largest Swiss banks, the Zürcher Kantonalbank, which has total assets of 167 billion Swiss francs. Until his retirement in 2018, he was the head of the tax and treasury functions of Senior PLC, an international manufacturing group listed on the London Stock Exchange.

Niels Kuster

Prof. Niels Kuster is the founder and Director of the Foundation for Research on Information Technologies in Society (IT’IS Foundation) in Zurich, Switzerland, and Associate Professor of the Department of Information Technology and Electrical Engineering at ETH Zurich. His research covers many aspects of electromagnetics and computational life sciences, including TI. He is a long-time member of several standardization bodies and serves as a consultant on exposure safety assessment for governmental agencies around the globe.

Esra Neufeld

Dr. Esra Neufeld is Associate Director of the Foundation for Research on Information Technologies in Society (IT’IS Foundation) in Zurich, Switzerland, and Head of the Computational Life Science group at IT’IS. He leads several research teams on advanced multiphysics simulation in medicine, treatment-planning software, medical image analysis and anatomical model generation, applied simulations, particularly in the field of bio-electromagnetics and electromagnetic-tissue interactions (heating, neurostimulation, cell proliferation, etc.) as well as in silico clinical trials and standardization.

Alvaro Pascual-Leone

Prof. Alvaro Pascual-Leone is Professor of Neurology at Harvard Medical School and a Senior Scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, Boston, USA. He is a pioneer in the use of noninvasive brain stimulation and its application for the study of brain behavior relations and the development of diagnostic and therapeutic interventions in neuropsychiatry. His contributions range from technology development to basic neurobiological insights gained from animal studies and modeling approaches to human proof-of-principle and multicenter clinical trials.